PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield
New Jersey
07080-2449
United States
Website: http://www.ptcbio.com/
610 articles about PTC Therapeutics, Inc.
-
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
9/7/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.
-
PTC Therapeutics to Participate at Upcoming September 2023 Investor Conferences
8/30/2023
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
-
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
8/28/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 which is being held from Aug. 29 to Sept. 1 in Jerusalem, Israel.
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
8/3/2023
PTC Therapeutics, Inc. announced a corporate update and financial results for the second quarter ending June 30, 2023.
-
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
7/21/2023
PTC Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for the extension of the Evrysdi® marketing authorization to include infants under two months of age in the European Union.
-
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
7/20/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Aug. 3 , at 4:30 p.m. ET.
-
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
7/19/2023
PTC Therapeutics, Inc. announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 18, 2023
7/18/2023
PTC Therapeutics, Inc. announced that on July 13, 2023, the company approved non-statutory stock options to purchase an aggregate of 66,380 shares of its common stock and 30,685 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 11 new employees.
-
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
7/17/2023
PTC Therapeutics, Inc. announced the appointment of Pierre Gravier to the role of Chief Financial Officer.
-
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
7/11/2023
PTC Therapeutics, Inc., announced that the company will provide a virtual presentation on PKU including discussion of the current therapeutic and commercial landscape with an expert key opinion leader.
-
More than a month after failing its Friedrich’s ataxia trial, PTC Therapeutics’ vatiquinone has again missed its primary endpoint, this time in a mitochondrial disease-associated seizures study.
-
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
6/29/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reduction in observable motor seizures.
-
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
6/21/2023
PTC Therapeutics, Inc. today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington's disease (HD) patients.
-
The Huntington’s disease space saw a flurry of activity Wednesday as PTC and uniQure released data from their respective mid-phase trials.
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 15, 2023
6/15/2023
PTC Therapeutics, Inc. announced that on June 12, 2023, the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 23 new employees.
-
PTC Therapeutics to Participate at Upcoming Investor Conferences - June 2, 2023
6/2/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences.
-
Despite a disappointing showing in the Phase III MOVE-FA trial, PTC Therapeutics says it will move forward with regulatory talks for the Friedreich's ataxia treatment. Meanwhile, the company is discontinuing several early-stage gene therapies and reducing its headcount.
-
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
5/23/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.
-
PTC Therapeutics Announces Strategic Pipeline Prioritization
5/23/2023
PTC Therapeutics, Inc. announced the discontinuation of preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization.
-
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
5/17/2023
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria (PKU).